{
  "source": "PA-Med-Nec-Epsolay.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2283-3\nProgram Prior Authorization/Medical Necessity\nMedication Epsolay® (benzoyl peroxide)*\nP&T Approval Date 8/2022, 8/2023, 8/2024\nEffective Date 11/1/2024\n1. Background:\nEpsolay (benzoyl peroxide)* topical cream is indicated for the treatment of inflammatory\nlesions of rosacea in adults.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Epsolay* will be approved based on all of the following criteria:\na. Diagnosis of rosacea\n-AND-\nb. Treatment of inflammatory lesions\n-AND-\nc. History of failure (after a 30 day-trial), contraindication or intolerance to two of the\nfollowing:\n1) topical metronidazole cream or gel (generic Metrocream, Metrogel)\n2) Finacea (azelaic acid 15%)\n3) Soolantra (ivermectin 1% cream)\nAuthorization will be issued for 6 months.\nB. Reauthorization\n1. Epsolay* will be approved based on the following criterion:\na. Documentation of positive clinical response to therapy demonstrated by a reduction\nin inflammatory lesion counts\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services, Inc.\n1\n*Epsolay is typically excluded from coverage\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n4. References:\n1. Epsolay [package insert]. Fort Worth, TX: Galderma Laboratories, L.P. April 2023.\n2. Thiboutot D, Anderson R, Cook-Bolden F, Draelos Z, Gallo RL, Granstein RD, Kang S, Macsai\nM, Gold LS, Tan J. Standard management options for rosacea: The 2019 update by the National\nRosacea Society Expert Co",
    "ot D, Anderson R, Cook-Bolden F, Draelos Z, Gallo RL, Granstein RD, Kang S, Macsai\nM, Gold LS, Tan J. Standard management options for rosacea: The 2019 update by the National\nRosacea Society Expert Committee. J Am Acad Dermatol. 2020;82(6):1501-1510.\nProgram Prior Authorization/Medical Necessity - Epsolay\nChange Control\n8/2022 New program.\n8/2023 Added that Epsolay typically excluded. Included brand Finacea as trial\noption. Updated references.\n8/2024 Annual review. Removed that step therapy may be in place.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}